Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease
Authors:
Open Access
- 19 May 2010
- journal article
- research article
- Published by SAGE Publications in Vascular Medicine
- Vol. 15 (4) , 267-274
Abstract
Peripheral arterial disease (PAD) is associated with major cardiovascular morbidity and mortality. Abnormalities in nitric oxide metabolism due to excess of the NO synthase inhibitor asymmetric dimethylarginine (ADMA) may be pathogenic in PAD. We explored the association between ADMA levels and markers of atherosclerosis, function, and prognosis. A total of 133 patients with symptomatic PAD were enrolled. Ankle—brachial index (ABI), walking time, vascular function measures (arterial compliance and flow-mediated vasodilatation) and plasma ADMA level were assessed for each patient at baseline. ADMA correlated inversely with ABI (r = —0.238, p = 0.003) and walking time (r = —0.255, p = 0.001), independent of other vascular risk factors. We followed up 125 (94%) of our 133 initial subjects with baseline measurements (mean 35 months). Subjects with ADMA levels in the highest quartile (> 0.84 μmol/l) showed a significantly greater occurrence of a major adverse cardiovascular event (MACE) compared to those with ADMA levels in the lower three quartiles (p = 0.001). Cox proportional-hazards regression analysis revealed that ADMA was a significant predictor of MACE, independent of other risk factors including age, sex, blood pressure, smoking history, diabetes and ABI (hazard ratio = 5.1, p < 0.001). Measures of vascular function, such as compliance, flow-mediated vasodilatation (FMVD) and blood pressure, as well as markers of PAD severity, including ABI and walking time, were not predictive. In conclusion, circulating levels of ADMA correlate independently with measures of disease severity and major adverse cardiovascular events. Agents that target this pathway may be useful for this patient population. Clinical Trial Registration — URL: http:// www.clinicaltrials.gov. Unique identifier: NCT00284076Keywords
This publication has 50 references indexed in Scilit:
- Predictive Value of Reactive Hyperemia for Cardiovascular Events in Patients With Peripheral Arterial Disease Undergoing Vascular SurgeryArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetesAtherosclerosis, 2006
- ADMA Increases Arterial Stiffness and Decreases Cerebral Blood Flow in HumansStroke, 2006
- Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive diseaseProstaglandins & Other Lipid Mediators, 2006
- Dimethylarginine Dimethylaminohydrolase Overexpression Suppresses Graft Coronary Artery DiseaseCirculation, 2005
- Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatmentThe American Journal of Cardiology, 2005
- NITRIC OXIDE SYNTHASE: Role in the Genesis of Vascular DiseaseAnnual Review of Medicine, 1997
- L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans.Journal of Clinical Investigation, 1992
- Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit.Journal of Clinical Investigation, 1992
- Paradoxical Vasoconstriction Induced by Acetylcholine in Atherosclerotic Coronary ArteriesNew England Journal of Medicine, 1986